Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OTOJV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IKS-03
|
|||||
| Synonyms |
IKS 03; IKS-03; IKS03; LCB-73; LCB 73; LCB73; NI-2201; NI 2201; NI2201
Click to Show/Hide
|
|||||
| Organization |
Iksuda Therapeutics Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Pyrrolobenzo diazepine prodrug
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Tumor-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
